Bank of Montreal Can Sells 2,059,760 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Bank of Montreal Can lessened its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 98.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 26,562 shares of the biotechnology company's stock after selling 2,059,760 shares during the quarter. Bank of Montreal Can's holdings in ADMA Biologics were worth $456,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ADMA. GAMMA Investing LLC increased its position in shares of ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after buying an additional 967 shares during the period. Mark Sheptoff Financial Planning LLC bought a new stake in ADMA Biologics during the fourth quarter valued at $35,000. Vision Financial Markets LLC bought a new stake in ADMA Biologics in the fourth quarter worth approximately $51,000. AlphaQuest LLC bought a new stake in shares of ADMA Biologics in the 4th quarter valued at $84,000. Finally, CIBC Private Wealth Group LLC lifted its position in shares of ADMA Biologics by 137.1% during the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after acquiring an additional 2,954 shares during the period. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Trading Up 2.8 %

NASDAQ ADMA traded up $0.60 during trading on Thursday, hitting $22.33. 2,169,905 shares of the company's stock traded hands, compared to its average volume of 3,624,562. The stock has a fifty day moving average of $18.55 and a two-hundred day moving average of $18.26. ADMA Biologics, Inc. has a 12-month low of $6.26 and a 12-month high of $23.64. The firm has a market cap of $5.28 billion, a P/E ratio of 79.75 and a beta of 0.53. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.